Are Three Weeks of Whole-Breast Radiotherapy as Good as Five Weeks in Early Breast Cancer? − 10 Year Follow-Up in the Canadian Trial of Hypofractionated Radiation Therapy

摘要

Whole breast irradiation (WBI) is considered standard of care among both patients having undergone breast-conserving therapy for invasive breast carcinoma and selected cases post mastectomy. Since the introduction of WBI, clinical trials have been conducted to define the optimal dose, schedule and length of WBI aiming to increase efficacy while reducing toxicity. In the paper discussed in this issue's journal club, Whelan et al. present the latest in a series of randomized clinical trials on hypofractionated radiotherapy.